Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

Underneath the intricacy of every cancer lies mysterious events that impel the tumour cell and its posterity into abnormal growth and tissue invasion. Oncogenic mutations disturb the regulatory circuits responsible for the governance of versatile cellular functions, permitting tumour cells to endure...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease 2016-01, Vol.7 (1), p.e2058-e2058
Main Authors: Baig, S, Seevasant, I, Mohamad, J, Mukheem, A, Huri, H Z, Kamarul, T
Format: Article
Language:English
Subjects:
631/80/82/23
631/80/86
692/699/67/1059/602
Antibodies
Apoptosis
Biochemistry
Biomedical and Life Sciences
Cancer
Cell Biology
Cell Culture
Humans
Immunology
Life Sciences
Neoplasms - genetics
Neoplasms - pathology
Oncology
Pharmaceutical sciences
Review
Therapeutic Human Experimentation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Underneath the intricacy of every cancer lies mysterious events that impel the tumour cell and its posterity into abnormal growth and tissue invasion. Oncogenic mutations disturb the regulatory circuits responsible for the governance of versatile cellular functions, permitting tumour cells to endure deregulated proliferation, resist to proapoptotic insults, invade and erode normal tissues and above all escape apoptosis. This disruption of apoptosis has been highly implicated in various malignancies and has been exploited as an anticancer strategy. Owing to the fact that apoptosis causes minimal inflammation and damage to the tissue, apoptotic cell death-based therapy has been the centre of attraction for the development of anticancer drugs. Increased understanding of the molecular pathways underlying apoptosis has enabled scientists to establish unique approaches targeting apoptosis pathways in cancer therapeutics. In this review, we reconnoitre the two major pathways (intrinsic and extrinsic) targeted cancer therapeutics, steering toward chief modulators of these pathways, such as B-cell lymphoma 2 protein family members (pro- and antiapoptotic), inhibitor of apoptosis proteins, and the foremost thespian of extrinsic pathway regulator, tumour necrosis factor-related apoptosis-inducing agent. Together, we also will have a look from clinical perspective to address the agents (drugs) and therapeutic strategies adopted to target these specific proteins/pathways that have entered clinical trials.
ISSN:2041-4889
2041-4889
DOI:10.1038/cddis.2015.275